Stock HYPR HYPERFINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Hyperfine, Inc.

Equities

HYPR

US44916K1060

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
0.8 USD +0.90% Intraday chart for Hyperfine, Inc. -5.33% -28.57%
04-17 Hyperfine, Inc. Enroll First Alzheimer's Patients Receiving Amyloid-Targeting Therapy in Care PMR Study CI
03-22 Wells Fargo Trims Hyperfine's Price Target to $1.60 From $2.10, Keeps Equalweight Rating MT

Summary

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
HYPERFINE, INC. Stock Hyperfine, Inc.
-28.57% 57.1M -
SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD. Stock Shanghai United Imaging Healthcare Co., Ltd.
-3.25% 15.01B -
IRAY TECHNOLOGY COMPANY LIMITED Stock iRay Technology Company Limited
-38.91% 2.8B
C-
SONOSCAPE MEDICAL CORP. Stock SonoScape Medical Corp.
-12.68% 2.45B -
BEIJING WANDONG MEDICAL TECHNOLOGY CO.,LTD. Stock Beijing Wandong Medical Technology Co.,Ltd.
-12.18% 1.46B - -
CORETAG, INC. Stock Coretag, Inc.
-.--% 1.12B - -
NANO-X IMAGING LTD. Stock Nano-X Imaging Ltd.
+46.70% 534M -
DETECTION TECHNOLOGY OYJ Stock Detection Technology Oyj
+14.96% 245M
C
DRTECH CORPORATION Stock DRTECH Corporation
-13.03% 203M - -
VIEWORKS CO., LTD. Stock Vieworks Co., Ltd.
+2.59% 187M -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. HYPR Stock
  4. Ratings Hyperfine, Inc.